Is it Time to Dump Inhibrx Inc (INBX) Stock After it Has Gained 6.92% in a Week?

Inhibrx Inc (INBX) stock has risen 6.92% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Inhibrx Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on INBX!

See Full INBX Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With INBX Stock Today?

Inhibrx Inc (INBX) stock has gained 3.78% while the S&P 500 has fallen -0.45% as of 2:51 PM on Tuesday, Jun 20. INBX has gained $0.99 from the previous closing price of $26.20 on volume of 147,134 shares. Over the past year the S&P 500 has risen 16.60% while INBX has gained 177.45%. INBX lost -$3.94 per share in the over the last 12 months.

More About Inhibrx Inc

Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates. The company has four programs in clinical trials, of which three of the programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency. Click Here to get the full Stock Report for Inhibrx Inc stock.